Abbratech Inc Profile last edited on: 10/25/2023
CAGE: 8VPC6
UEI: G7S7M6L41EX5
Business Identifier: Recombinant antibodies: discovery and development services 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
25 Business Park Drive Suite C
Branford, CT 06405
Branford, CT 06405
| (203) 606-5394 |
| admin@abbratech.com |
| www.abbratech.com |
Location: Single
Congr. District: 03
County: New Haven
Congr. District: 03
County: New Haven
Public Profile
Launched by a team of experienced life science industry researchers. Abbratech Inc is structured around addressing various problems in the antibody development paradigm; that facts that the current systems are too slow and do not always result in consistent, renewable, and precise antibodies. The technology and approach devised by Abbratechs - designated EPIVOLVEsm technology - provides a comprehensive custom recombinant antibody discovery and development services platform.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2024 | 2 | NIH | $2,160,481 | |
| Project Title: Platform for the High Throughput Generation and Validation of Affinity Reagents | ||||
| 2024 | 2 | NIH | $1,291,874 | |
| Project Title: Structure-guided neutralizing antibodies developed using EpiVolve technology | ||||
| 2023 | 1 | NIH | $295,460 | |
| Project Title: T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy | ||||
| 2023 | 2 | NIH | $1,461,121 | |
| Project Title: Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins. I. survey of existing antibodies, and II. development of method improvements | ||||
| 2022 | 1 | NIH | $253,440 | |
| Project Title: Method for the isolation of antibodies with functional activity against cell surface targets | ||||
Key People / Management
Michael P Weiner -- CEO & Founder
Xiaofeng Li
Linda Stevens -- Executive Director
Xiaofeng Li
Linda Stevens -- Executive Director
Company News
There are no news available.
